More about Archean Chemical Industries Limited
Fundamentals for Archean Chemical Industries Limited
Regulatory Filings for Archean Chemical Industries Limited
Defence Profits Reach Dharavi's Machinists
From COVID Debt to Green Despair: Industrial Discharge Is Destroying India’s Last Prawn Nurseries
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
Fundamentals for Archean Chemical Industries Limited
Business Operations:
Sector: Basic MaterialsIndustry: Chemicals
Archean Chemical Industries Limited manufactures and sells specialty marine chemicals in India and internationally. It offers bromine for use in pharmaceuticals, agrochemicals, flame retardants, and water treatment products, as well as oil and gas, and energy storage industries; industrial salt for chloralkali chemical, food and beverage, water treatment, and oil and gas industries; and sulphate of potash, an inorganic salt for agrochemicals, medical, glass, cosmetics, etc. Industries. The company was founded in 2003 and is based in Chennai, India.
Revenue projections:
Investors may react cautiously to news that ACI's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 23.26923 |
| debtToEquity | 14.78200 |
| earningsGrowth | -0.50500 |
| revenueGrowth | 0.05100 |
| grossMargins | 0.95173 |
| operatingMargins | 0.12097 |
| trailingEps | 11.84000 |
| forwardEps | 26.00000 |
ACI's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
ACI's low Debt-to-Equity ratio demonstrates that the company maintains a healthy balance between equity and debt, avoiding over-leverage. This suggests a low-risk financial profile, giving investors confidence in the company's stability and ability to manage its financial commitments.
ACI's low earnings and revenue growth suggest that the company may face shrinking profits. This could indicate underlying financial challenges, making it difficult for ACI to sustain its current profitability.
ACI's negative gross and operating margins suggest that the company is currently losing money, unable to generate profit from production or operations. This could signal inefficiencies in cost control or a drop in sales.
ACI's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that ACI is likely to outperform its previous year's financial performance.
Price projections:
Price projections for ACI have been revised down over time, reflecting a less optimistic outlook. Analysts appear to be adjusting their expectations, signaling concerns about the company's ability to sustain its previous growth levels.
Insider Transactions:
1 transactions to buy ACI shares were recorded, with market price at 627.5499877929688.Throughout the period under consideration, no buy transactions were recorded.ACI has experienced more selling activity at current price levels, which could suggest a bearish outlook. If the trend of increased selling continues, it may result in further price declines for the stock.
Recommendation changes over time:
A recent buy bias from analysts toward ACI indicates strong confidence in the stock's future performance. This could encourage investors to park their money in ACI, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy